| Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ... Journal of the National Cancer Institute 103 (7), 553-561, 2011 | 537 | 2011 |
| Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. S Redaelli, R Piazza, R Rostagno, V Magistroni, P Perini, M Marega, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 520 | 2008 |
| Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias CB Gambacorti-Passerini, RH Gunby, R Piazza, A Galietta, R Rostagno, ... The lancet oncology 4 (2), 75-85, 2003 | 517 | 2003 |
| In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells M Puttini, AML Coluccia, F Boschelli, L Cleris, E Marchesi, ... Cancer research 66 (23), 11314-11322, 2006 | 483 | 2006 |
| Recurrent SETBP1 mutations in atypical chronic myeloid leukemia R Piazza, S Valletta, N Winkelmann, S Redaelli, R Spinelli, A Pirola, ... Nature genetics 45 (1), 18-24, 2013 | 429 | 2013 |
| Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase–positive lymphoma patients C Gambacorti Passerini, F Farina, A Stasia, S Redaelli, M Ceccon, ... Journal of the National Cancer Institute 106 (2), djt378, 2014 | 316 | 2014 |
| Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study S Mori, E Vagge, P Le Coutre, E Abruzzese, B Martino, E Pungolino, ... American journal of hematology 90 (10), 910-914, 2015 | 237 | 2015 |
| In reply to'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' C Gambacorti, L Tornaghi, A Franceschino, R Piazza, G Corneo, ... Nature medicine 13 (1), 13-14, 2007 | 162 | 2007 |
| A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype A Forlino, R Piazza, C Tiveron, SD Torre, L Tatangelo, L Bonafe, ... Human molecular genetics 14 (6), 859-871, 2005 | 153 | 2005 |
| Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition PS Bachmann, RG Piazza, ME Janes, NC Wong, C Davies, A Mogavero, ... Blood, The Journal of the American Society of Hematology 116 (16), 3013-3022, 2010 | 141 | 2010 |
| Recurrent ETNK1 mutations in atypical chronic myeloid leukemia CB Gambacorti-Passerini, C Donadoni, A Parmiani, A Pirola, S Redaelli, ... Blood, The Journal of the American Society of Hematology 125 (3), 499-503, 2015 | 130 | 2015 |
| Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors S Redaelli, L Mologni, R Rostagno, R Piazza, V Magistroni, M Ceccon, ... American journal of hematology 87 (11), E125, 2012 | 126 | 2012 |
| Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis L Campiotti, MB Suter, L Guasti, R Piazza, C Gambacorti-Passerini, ... European Journal of Cancer 77, 48-56, 2017 | 108 | 2017 |
| Lorlatinib treatment elicits multiple on-and off-target mechanisms of resistance in ALK-driven cancer S Redaelli, M Ceccon, M Zappa, GG Sharma, C Mastini, M Mauri, ... Cancer research 78 (24), 6866-6880, 2018 | 95 | 2018 |
| SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub R Piazza, V Magistroni, S Redaelli, M Mauri, L Massimino, A Sessa, ... Nature communications 9 (1), 2192, 2018 | 87 | 2018 |
| Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity A Graudenzi, D Maspero, F Angaroni, R Piazza, D Ramazzotti Iscience 24 (2), 2021 | 70 | 2021 |
| The co-evolution of the genome and epigenome in colorectal cancer T Heide, J Househam, GD Cresswell, I Spiteri, C Lynn, M Mossner, ... Nature 611 (7937), 733-743, 2022 | 69 | 2022 |
| Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK–positive anaplastic large cell lymphoma M Ceccon, L Mologni, G Giudici, R Piazza, A Pirola, D Fontana, ... Molecular Cancer Research 13 (4), 775-783, 2015 | 67 | 2015 |
| 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia D Di Giacomo, R La Starza, P Gorello, F Pellanera, Z Kalender Atak, ... Blood, The Journal of the American Society of Hematology 138 (9), 773-784, 2021 | 61 | 2021 |
| Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex R Piazza, V Magistroni, A Mogavero, F Andreoni, C Ambrogio, R Chiarle, ... Neoplasia 15 (5), 511-IN17, 2013 | 58 | 2013 |
